- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07937410
Chronic Subdural Hematoma Recurrence (cSDH RCT)
The Effect of Dextrose 5% in 0.225% Sodium Chloride (D5 ¼NS) on Postoperative Chronic Subdural Hematoma Size and Recurrence Rate: a Prospective, Randomized, Double-blinded, Placebo Controlled Clinical Trial
How can investigators improve recurrence rates of chronic subdural hematomas to reduce need for surgical intervention? Study investigators hypothesize that Dextrose 5% in 0.225% Sodium Chloride (D5 ¼NS) will increase the intracellular brain volume and water content post-operatively, reducing the residual subdural space that is created by evacuation of the chronic subdural hematoma (CSDH), and that this, in turn, will reduce the hematoma volume that will then potentially lead to improved functional outcomes, reduced hospitalization time as well as the reduced rate of symptomatic recurrence requiring redo surgery.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The proposed study is a randomized, placebo controlled clinical trial to investigate the effects of D5 ¼NS (treatment) vs. NS (placebo) on residual cSDH volume after surgical drainage via a craniotomy or burr holes.
Participants in the study will be adult patients who had presented with imaging evidence (based on non-contrast head CT) of cSDH requiring surgical evacuation (craniotomy or burr holes). Patients in this study will receive either 5% dextrose ¼Normal Saline (treatment) or Normal Saline (placebo) for 24h after surgery. The study group assignment will be performed based on randomization process prior to the surgery. All the patients will be undergoing a head CT without contrast imaging at 24h after surgery. The residual hematoma volume will be calculated based on XYZ/2 method as previously described (Sucu et al., 2005).
The bedside nursing staff will be provided with either the placebo or D5 ¼NS solutions from the pharmacy in an opaque bag to be administered to the patient after the randomization process has taken place. The procedure for the placebo and treatment solution administration is the same as the standard intravenous fluid administration procedure except the fact of an opaque covering and maintenance of the blinding throughout the process. The bedside nursing staff will administer the intravenous fluid. The infusion rate, as stated, will be 100 cc/h for 24h after SDH evacuation surgery at which time a standard of care head CT without contrast will be obtained. This will be a double-blinded study where blinding will be achieved via the prerandomized enrollment log. Participants signing the consent will be enrolled based on time of enrollment and study ID will be prelinked to a study group of normal saline (placebo) or D51/4NS solution. Pharmacy who will be documenting the treatment allocation and will be issuing the IV fluid for each of the patients will be maintaining the blinding status. The pharmacy staff and coordinator will be the only individuals holding the blinding key which will be released at the official end of the study after all the datapoints have been gathered for all the participants. Additionally, the patients will have basic metabolic panel (BMP as standard of care ) labs drawn every 12 hours during the 24 hour treatment period to assess the electrolyte status and any adverse reactions. The PI and all other study team members, other than the randomizing coordinator, will remain blinded. The unblinded coordinator will not perform any clinical assessments and will not share blinding information with any other team members.
Symptomatic recurrence rates requiring redo surgery within a 90-day period (+/- 7 days) after the initial surgery will be identified via the chart review of each individual study participant.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Jordan Darden, PhD
- Phone Number: 540-529-7792
- Email: jadarden@carilionclinic.org
Study Contact Backup
- Name: Kristine Ravina, MD
- Phone Number: 540-224-5170
- Email: kravina@carilionclinic.org
Study Locations
-
-
Virginia
-
Roanoke, Virginia, United States, 24014
- Recruiting
- Carilion Clinic
-
Contact:
- Jordan Darden, PhD
- Phone Number: 540-529-7792
- Email: jadarden@carilionclinic.org
-
Principal Investigator:
- Eric Marvin, DO
-
Contact:
- Kristine Ravina, MD
- Phone Number: 540-224-5170
- Email: kravina@carilionclinic.org
-
Sub-Investigator:
- Kristine Ravina, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Written and voluntarily given informed consent
- If the patient cannot give informed consent, a legally authorized representative may provide it
- Male or female 18-100
- Imaging evidence indicative of cSDH
- The neurosurgical team has determined that the patient requires surgical evacuation of the cSDH
Exclusion Criteria:
- significant/symptomatic hyperglycemia; specifically diabetic ketoacidosis or fasting blood glucose level >200 mg/dl
- Patients with significant hyponatremia (Na <130 mEq/L)
- Patients who are judged by investigators as being ineligible for participation in the study Patients with a history of relevant drug hypersensitivity Patients who receive another investigational drug shortly before acquisition of consent Women who are pregnant or breastfeeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: normal saline
normal saline |
normal saline
Other Names:
|
|
Active Comparator: saline with dextrose (D5 ¼NS solutions)
saline with dextrose (D5 ¼NS solutions) |
D5 ¼NS solutions
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Comparative residual CSDH volume (in mm3) measured and calculated using head CT
Time Frame: 24 hours after surgery
|
Comparative residual CSDH volume (in mm3) measured and calculated using head CT |
24 hours after surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
ICU and overall hospitalization length of stay
Time Frame: duration of total hospital stay assessed for up to 6 months
|
ICU and overall hospitalization length of stay. |
duration of total hospital stay assessed for up to 6 months
|
|
Functional improvement as measured using mRS scale scores upon admission
Time Frame: follow up post surgery assessment up to 6 weeks post release
|
Functional improvement as measured using mRS scale scores upon admission, scoring from 0-6, low score with no symptoms and 6 indicating death |
follow up post surgery assessment up to 6 weeks post release
|
|
Symptomatic recurrence rates requiring redo surgery within a 90-day period (+/- 7 days) after the initial surgery
Time Frame: 90 days post surgery
|
Symptomatic recurrence rates requiring redo surgery within a 90-day period (+/- 7 days) after the initial surgery |
90 days post surgery
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Eric Marvin, DO, Carilion Clinic
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Vascular Diseases
- Cardiovascular Diseases
- Wounds and Injuries
- Pathologic Processes
- Chronic Disease
- Disease Attributes
- Hemorrhage
- Craniocerebral Trauma
- Trauma, Nervous System
- Intracranial Hemorrhages
- Intracranial Hemorrhage, Traumatic
- Pathological Conditions, Signs and Symptoms
- Hematoma, Subdural
- Hematoma
- Recurrence
- Hematoma, Subdural, Chronic
- Pharmaceutical Preparations
- Carbohydrates
- Inorganic Chemicals
- Chlorine Compounds
- Crystalloid Solutions
- Isotonic Solutions
- Solutions
- Sugars
- Sodium Compounds
- Hexoses
- Monosaccharides
- Chlorides
- Hydrochloric Acid
- Saline Solution
- Glucose
- Sodium Chloride
Other Study ID Numbers
- IRB-23-2036
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.